Adil I. Daud
Experienced in Oral Squamous Cell Carcinoma

Dr. Adil I. Daud

Oncology | Hematology
University Of California San Francisco
400 Parnassus Ave, Mcb300, 
San Francisco, CA 
Offers Telehealth
Experienced in Oral Squamous Cell Carcinoma
University Of California San Francisco
400 Parnassus Ave, Mcb300, 
San Francisco, CA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Adil Daud is an Oncologist and a Hematologist in San Francisco, California. Dr. Daud is rated as an Experienced provider by MediFind in the treatment of Oral Squamous Cell Carcinoma. His top areas of expertise are Melanoma, Merkel Cell Carcinoma, Melanoma of the Eye, and Neuroendocrine Tumor.

His clinical research consists of co-authoring 165 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Oncology
Hematology
Licenses
Internal Medicine in FL
Hospital Affiliations
Ucsf Medical Center
Languages Spoken
English
Gender
Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Net

Accepted plan types not found. Please verify directly with the provider.

Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Western Health Advantage
  • HMO
  • INSURANCE PLAN
  • MEDICARE DISCOUNT CARD
  • MEDICARE MAPD
View 6 Less Insurance Carriers -

Locations

UNIVERSITY OF CALIFORNIA SAN FRANCISCO
400 Parnassus Ave, Mcb300, San Francisco, CA 94143

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Biological, Drug, Other
Study Drugs: Dabrafenib, Trametinib, Spartalizumab (PDR001)
Study Phase: Phase 3
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Enrollment Status: Completed
Publish Date: September 17, 2025
Intervention Type: Procedure
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
A Randomized, Open-label, Multi-arm, Two-part, Phase II Study to Assess Efficacy and Safety of Multiple LXH254 Combinations in Patients With Previously Treated Unresectable or Metastatic BRAFV600 or NRAS Mutant Melanoma
Enrollment Status: Active_not_recruiting
Publish Date: July 31, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 2
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
An Open-label, Phase 2 Basket Study of SEA-CD40 Combination Therapies in Advanced Malignancies
Enrollment Status: Completed
Publish Date: May 11, 2025
Intervention Type: Drug
Study Drugs: SEA-CD40, Pembrolizumab, Pemetrexed, Carboplatin
Study Phase: Phase 2
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
A Phase Ib, Open-label, Multicenter Study of Oral LXH254-centric Combinations in Adult Patients With Advanced or Metastatic KRAS or BRAF Mutant Non-Small Cell Lung Cancer or NRAS Mutant Melanoma
Enrollment Status: Terminated
Publish Date: April 13, 2025
Intervention Type: Drug
Study Drugs: LXH254, LTT462, Trametinib, Ribociclib
Study Phase: Phase 1
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma
Enrollment Status: Completed
Publish Date: June 18, 2024
Intervention Type: Drug
Study Drugs: Spartalizumab, LAG525, Capmatinib, Canakinumab, Ribociclib
Study Phase: Phase 2
A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
A Phase II Randomized Study of Tiragolumab Plus Atezolizumab Versus Atezolizumab in the Treatment of Stage II Melanoma Patients Who Are ctDNA-positive Following Resection
Enrollment Status: Terminated
Publish Date: February 20, 2024
Intervention Type: Drug, Device
Study Drugs: Atezolizumab, Tiragolumab
Study Phase: Phase 2
Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma
Prostaglandin Inhibition and Programmed Cell Death Protein 1 (PD-1)/Cytotoxic T-lymphocyte-Associated Protein 4 (CTLA4) Blockade in Melanoma
Enrollment Status: Completed
Publish Date: October 13, 2022
Intervention Type: Biological, Other, Drug
Study Drugs: Aspirin, Ipilimumab, Pembrolizumab
Study Phase: Phase 2
A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)
A Phase 1/2 Trial of BKM120 Combined With Vemurafenib (PLX4032) in BRAFV600E/K Mutant Advanced Melanoma (Novartis Study Number CBKM120ZUS21T)
Enrollment Status: Completed
Publish Date: August 17, 2020
Intervention Type: Drug
Study Phase: Phase 1/Phase 2
A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
A Phase II Trial of Targeted Kinase Fusion Inhibition in Unresectable Stage III/IV BRAF/NRAS Wild-Type Melanoma
Enrollment Status: Terminated
Publish Date: January 27, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

165 Total Publications

Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Phase 1b/2 study evaluating safety, efficacy and immune effects of TLR9 agonist cavrotolimod with anti-PD-1 antibodies among patients with advanced solid tumors.
Journal: Journal for immunotherapy of cancer
Published: July 04, 2025
Similar Doctors
Distinguished in Oral Squamous Cell Carcinoma
Dr. Alexander D. Colevas
Oncology | Hematology Oncology
Distinguished in Oral Squamous Cell Carcinoma
Dr. Alexander D. Colevas
Oncology | Hematology Oncology

Stanford Health Care

300 Pasteur Dr, 
Stanford, CA 
 (27.6 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alexander Colevas is an Oncologist and a Hematologist Oncology provider in Stanford, California. Dr. Colevas is rated as a Distinguished provider by MediFind in the treatment of Oral Squamous Cell Carcinoma. His top areas of expertise are Nasopharyngeal Carcinoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Oral Squamous Cell Carcinoma, and Thyroid Cancer.

Alain P. Algazi
Advanced in Oral Squamous Cell Carcinoma
Dr. Alain P. Algazi
Hematology Oncology | Hematology | Oncology
Advanced in Oral Squamous Cell Carcinoma
Dr. Alain P. Algazi
Hematology Oncology | Hematology | Oncology

University Of California San Francisco

1600 Divisadero St, 
San Francisco, CA 
 (1.7 miles away)
415-476-1000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Alain Algazi is a Hematologist Oncology specialist and a Hematologist in San Francisco, California. Dr. Algazi is rated as an Elite provider by MediFind in the treatment of Oral Squamous Cell Carcinoma. His top areas of expertise are Melanoma, Head and Neck Squamous Cell Carcinoma (HNSCC), Polymorphous Low Grade Adenocarcinoma, and Glioma.

Advanced in Oral Squamous Cell Carcinoma
Dr. Hyunseok P. Kang
Hematology Oncology | Oncology
Advanced in Oral Squamous Cell Carcinoma
Dr. Hyunseok P. Kang
Hematology Oncology | Oncology

Regents Of The University Of California

1600 Divisadero St, 
San Francisco, CA 
 (1.7 miles away)
415-476-4029
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Hyunseok Kang is a Hematologist Oncology specialist and an Oncologist in San Francisco, California. Dr. Kang is rated as a Distinguished provider by MediFind in the treatment of Oral Squamous Cell Carcinoma. His top areas of expertise are Adenoid Cystic Carcinoma, Salivary Gland Tumors, Nasopharyngeal Carcinoma, Thyroid Cancer, and Gastrostomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Daud's expertise for a condition
ConditionClose
View All 33 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile